尽管已经构建了刺激响应性超分子自组装体,很少报道基于主体-客体-共轭单体(HGCM)的这些超分子自组装体的形态转变诱导的受控药物递送。在本文中,AB2型HGCM的自组装行为,例如,β-环糊精-苯并咪唑2(β-CD-BM2),在中性和酸性pH条件下进行了研究,分别。具体来说,β-CD-BM2首先在中性pH值下自组装成流体动力学直径为163nm的扇形超分子自组装体,而它们在酸性条件下进一步解离成尺寸为52nm的球形超分子自组装体。该形态转变过程用于在中性和酸性pH下进行两阶段DOX递送。基础细胞实验表明,不同形态的基于β-CD-BM2的载药超分子自组装体可以抑制癌细胞的增殖,表明了它们在药物输送领域的潜在应用。
Although stimuli-responsive supramolecular self-assemblies have been constructed, the controlled drug delivery induced by morphology transitions of these supramolecular self-assemblies on the basis of host-guest-conjugated monomers (HGCMs) are few reported. In this paper, the self-assembly behaviors of AB2-type HGCMs, e.g., β-cyclodextrin-benzimidazole2 (β-CD-BM2), were investigated at neutral and acidic pH conditions, respectively. Specifically, β-CD-BM2 first self-assembled into fan-shaped supramolecular self-assemblies with a hydrodynamic diameter of 163 nm at neutral pH, whereas they were further dissociated into spherical supramolecular self-assemblies with a size of 52 nm under acidic conditions. This morphology transition process was utilized to conduct a two-stage DOX delivery under neutral and acidic pH. Basic cell experiments demonstrated that the drug-loaded β-CD-BM2-based supramolecular self-assemblies with varied morphology could inhibit cancer cell proliferation, indicating their potential application in the field of drug delivery.